rs1042640 - UGT1A8, UGT1A7, UGT1A1, UGT1A3, UGT1A5, UGT1A10, UGT1A6, UGT1A4, UGT1A9

Magnitude 2.2 · 3 studies on file

Reported associations

  • Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. - The Journal of antimicrobial chemotherapy (2015) · Nishijima T, Tsuchiya K, Tanaka N, Joya A, Hamada Y, Mizushima D, Aoki T, Watanabe K, Kinai E, Honda H, Yazaki H, Tanuma J, Tsukada K, Teruya K, Kikuchi Y, Oka S, Gatanaga H · PubMed 25151207

    Ritonavir-boosted atazanavir (atazanavir/ritonavir) is a widely used antiretroviral drug, though it can potentially cause nephrolithiasis. The aim of this study was to determine the relationship between polymorphisms in genes encoding proteins involved in metabolism and transportation of atazanavir, and atazanavir/ritonavir-induced nephrolithiasis in HIV-1-infected patients treated with atazanavir/ritonavir. Nineteen SNPs in the ABCB1, NR1I2, UGT1A1, SLCO1B1 and CYP3A5 genes were examined in case patients with atazanavir/ritonavir-induced nephrolithiasis (n = 31) and controls (n = 47). Case patients were those with a clinical diagnosis of nephrolithiasis while on atazanavir/ritonavir, based on new-onset acute flank pain plus one of the following: (i) new-onset haematuria; (ii) documented p

  • The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. - The Journal of pharmacology and experimental therapeutics (2013) · Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan SX, Greenblatt DJ, Lee WM · PubMed 23408116

    Acetaminophen is cleared primarily by hepatic glucuronidation. Polymorphisms in genes encoding the acetaminophen UDP-glucuronosyltransferase (UGT) enzymes could explain interindividual variability in acetaminophen glucuronidation and variable risk for liver injury after acetaminophen overdose. In this study, human liver bank samples were phenotyped for acetaminophen glucuronidation activity and genotyped for the major acetaminophen-glucuronidating enzymes (UGTs 1A1, 1A6, 1A9, and 2B15). Of these, only three linked single nucleotide polymorphisms (SNPs) located in the shared UGT1A-3'UTR region (rs10929303, rs1042640, rs8330) were associated with acetaminophen glucuronidation activity, with rs8330 consistently showing higher acetaminophen glucuronidation at all the tested concentrations of a

  • Genetics of 35 blood and urine biomarkers in the UK Biobank - Unknown journal (n.d.) · Unknown authors · PubMed 33462484

    ABSTRACT: Clinical laboratory tests are a critical component of the continuum of care. We evaluate the genetic basis of 35 blood and urine laboratory measurements in the UK Biobank (n=363,228 individuals). We identify 1,857 loci associated with at least one trait, containing 3,374 fine-mapped associations, and additional sets of large-effect (> 0.1 sd) protein-altering, HLA, and copy-number variant associations. Through Mendelian Randomization analysis, we discover 51 causal relationships, including previously known agonistic effects of urate on gout and cystatin C on stroke. Finally, we develop polygenic risk scores for each biomarker and built 'multi-PRS' models for diseases using 35 PRSs simultaneously, which improved chronic kidney disease, type 2 diabetes, gout, and alcoholic cirr


Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Bloodwork

  • serum total bilirubin levels Moderate

    C allele is strongly associated with elevated total bilirubin (GWAS p=1e-30, n=354K), reflecting reduced UGT1A activity affecting bilirubin conjugation

    Obtain baseline bilirubin; repeat annually or if symptoms suggest hyperbilirubinemia (jaundice, dark urine)

    • GWAS_CATALOG:33462484

Discuss with your doctor

  • atazanavir/ritonavir dosing and nephrolithiasis risk Moderate

    UGT1A activity influences atazanavir metabolism; CC and CG genotypes confer lower nephrolithiasis risk, while GG genotype increases risk when taking atazanavir/ritonavir

    If HIV+ on atazanavir/ritonavir, share genotype with HIV physician to inform drug choice and kidney stone monitoring

    • PharmGKB:UGT1A:CC
    • PharmGKB:UGT1A:CG
    • PharmGKB:UGT1A:GG

Drug interactions

  • acetaminophen (paracetamol) use Moderate

    CC genotype is associated with reduced UGT1A enzyme activity, impairing acetaminophen metabolism and increasing risk of unintentional liver injury and failure

    Use alternative analgesics (ibuprofen, naproxen); if acetaminophen necessary, discuss safe dosing limits with physician

  • acetaminophen dosing caution Moderate

    CG genotype is associated with intermediate UGT1A activity, reducing but not eliminating risk of acetaminophen-related liver injury compared to GG genotype

    Use standard dosing; avoid exceeding recommended limits; discuss risks with physician if frequent use